|
|
|
|
A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.
|
|
|
|
|
Players from across the biomanufacturing space, from academia to small biotechs to larger companies, must contend to arrive at an autologous therapy production process that can enable operators to minimize variability, control costs, and serve as many patients as possible.
|
|
|
|
|
Next-generation sequencing (NGS) accelerates therapy development by enabling rapid, cost-effective DNA/RNA analysis crucial for cell and gene therapies, process optimization, and impurity detection.
|
|
|
|
|
Built to support CGT commercial manufacturing, this facility enables multi-product production with a focus on scalability, faster timelines, and strict compliance. It features capacity slot planning, modular suites, and a strong digital infrastructure.
|
|
|
|
|
Read how a new partnership is advancing base editing therapy for sickle cell disease, combining cutting-edge science with streamlined manufacturing to accelerate clinical trials.
|
|
|
